DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Stelo, a new over-the-counter glucose biosensor designed for adults with prediabetes and Type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

DexCom Inc.

In a report released today, Josh Jennings from TD Cowen reiterated a Buy rating on Dexcom, with a price target of $95.00. Jennings covers the Healt...

TD Cowen Remains a Buy on Dexcom (DXCM)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Dexcom (DXCM), Fractyl Health, Inc. (GUTS) and BioNTech SE (BNTX)...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Dexcom (DXCM), Fractyl Health, Inc. (GUTS) and BioNTech SE (BNTX)

In a report released yesterday, Larry Biegelsen from Wells Fargo assigned a Buy rating to Dexcom, with a price target of $85.00. The company’s shar...

Wells Fargo Releases a Buy Rating on Dexcom (DXCM)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on CVS Health (CVS), Dexcom (DXCM) and HCA Healthcare (...

Current Quarter	$0.6	Next Quarter	$0.67
Current Year	$2.58	Next Year	$3.04
QoQ Growth	+11.7%	YoY Growth	+17.8%
3Y EPS CAGR	+34.5%	Target Price	$83.46
Consensus	Buy	Upside	+15.2%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	DXCM	$72.47	+1.74%	8.57M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	DXCM	$72.47	+1.7%	8.57M
3
4
5
6

DXCM

DXCM

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get DexCom Inc. Data in Excel

Get DexCom Inc. Data in Excel